Uncovering Mechanisms Associated With ADT Resistance in Prostate Cancer

Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

Dr. Goodrich presented the possible underlying mechanisms associated with androgen deprivation therapy (ADT) resistance and suggests an epigenetic approach for extending the clinical benefits of ADT at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers

Roman Fabbricatore
April 24th 2025
Article

Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Ariana Pelosci
April 17th 2025
Article

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

PROSTOX ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore
April 9th 2025
Article

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.